FDA
-
-
-
-
-
-
-
Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
-
-
-
-
-
-
-
Longeveron Chief Science Officer and Chief Medical Officer Selected as Speakers at the Global CardioVascular Clinical Trialists (CVCT) Forum
-
-
-
-
-
-
-
Longeveron receives US patent for stem cell therapy treating frailty
-
-
-
-
-
-
-
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
-
-
-
-
-
-
-
Longeveron Announces Closing Of Up To $17.5 Million Public Offering
-
-
-
-
-
-
-
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
-
-
-
-
-
-
-
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

